In this video, Bridget F. Koontz, MD, provides an expert opinion on the methods and findings of the study, “Dose-escalated radiotherapy alone or in combination with short-term androgen suppression for intermediate risk prostate cancer: outcomes from the NRG Oncology/RTOG 0815 randomized trial,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.
HUMC provides groundbreaking focal therapy for prostate cancer
September 13th 2023The Focal One high intensity focused ultrasound system uses precision sound waves to destroy prostate tumor tissue and spare healthy tissue, reducing the risk of side effects that would lower a patient's quality of life.
2 Clarke Drive
Cranbury, NJ 08512